Advertisement
The new investment capital will support continued advancement of thecompany's novel technology for therapeutic antibody discovery andoptimization, and building a pipeline of product candidates.
Advertisement
"We are pleased to have attracted such a strong investor group to supportthe company's multiple development programs," said Tom Smart, chairman andchief executive officer of Anaptys. "In addition to providing significantfinancial resources, these experienced investors bring Anaptys a wealth ofoperational, medical, and industry expertise along with key relationships thatwill serve the company well during this important stage of growth andachievement."
In connection with the financing, Heath Lukatch, Ph.D., of Novo A/S, JamesN. Topper, M.D., Ph.D., of Frazier Healthcare Ventures, and J. Leighton Read,M.D., of Alloy Ventures will join the Anaptys Board of Directors together withexisting members Kevin J Kinsella of Avalon Ventures, Nick Lydon, Ph.D., ofGranite Biopharma, LLC, R. Scott Greer of Numenor Ventures, and Anaptysexecutives William Boyle, Ph.D., and Tom Smart.
"It is a great pleasure for Novo A/S to lead this investment in Anaptys,"said Dr. Lukatch. "The company has developed powerful technologies to quicklyand cost effectively optimize antibodies against a variety of high valuetargets. By harnessing the efficiency of somatic hypermutation for antibodyevolution and optimization, Anaptys' innovative Omnitope-SHM(TM) System hasthe potential to usher in a new generation of best-in-class therapeuticantibodies."
About Anaptys Biosciences, Inc.
Anaptys is a privately-held developer of therapeutic antibody products andthe leader in the use of SHM for antibody discovery and optimization. SHM, orsomatic hypermutation, is the body's natural process for generating antibodydiversity to fight disease. The company's Omnitope-SHM(TM) System utilizes thekey components of SHM to enable the rapid generation and selection ofantibodies for therapeutic applications. The versatile platform can be appliedto the de novo discovery and optimization of antibodies directed to a chosendisease target, as well as affinity mature an existing antibody to improve itsbinding potency. Anaptys is using the platform to build a pipeline of productcandidates with significant medical and commercial potential. For moreinformation, visit the company's web site at http://www.anaptysbio.com.
About Novo A/S
Novo A/S is the holding company of the Novo Group, and is wholly owned bythe Novo Nordisk Foundation. Novo A/S was established in 1999 to manage theassets of the Foundation and actively make investments on behalf of theFoundation. Novo Ventures is recognized as a significant force within lifescience venture capital and is active in both Europe and North America. TheNovo Ventures team consists of six Partners in Copenhagen, one in London, andtwo in San Francisco.
With an evergreen structure, Novo A/S annually invests approximately $90million in venture capital into private life sciences companies and acts at apace comparable to a traditional $400 million fund. Novo A/S is not acorporate strategic fund; the group invests for financial rather thanstrategic returns. In total, Novo A/S has more than $10 billion undermanagement, which includes significant shareholdings in the independentlyoperating and publicly listed companies Novo Nordisk A/S and Novozymes A/S.For more informati
